Focus: Melius Pharma is a Swedish-headquartered public pharmaceutical company focused on interstitial lung disease treatment, specifically idiopathic pulmonary fibrosis. The company operates as a specialty pharma player with a narrow therapeutic focus on respiratory indications.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
Melius Pharma is a pre-revenue specialty player with interesting science but limited near-term hiring and unclear financial stability—only pursue if mission-driven in IPF and willing to accept execution risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Melius Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Melius Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles